

CLAIMS:

1. A method for determining the onset or a predisposition to the onset of a neoplasm in an individual, said method comprising measuring the level of expression of one or more:

- (i) nucleic acid molecules comprising a nucleotide sequence substantially as set forth in any one of SEQ ID NOs: 1-2, SEQ ID NOs: 4-6, SEQ ID NOs: 8-32, SEQ ID NOs: 35-37, SEQ ID NO: 38, SEQ ID NOs: 40-43, SEQ ID NOs: 45-49, SEQ ID NOs: 58-60, SEQ ID NO: 62, SEQ ID NOs: 64-66, SEQ ID NOs: 68-72 or SEQ ID NOs: 337-338 or a functional derivative, variant or homologue of said nucleic acid molecule; or
- (ii) nucleic acid molecules comprising a nucleotide sequence capable of hybridising any one or more of the sequences of (i) under low stringency conditions at 42°C or a functional derivative, variant or homologue of said nucleic acid molecule

in a biological sample from said individual wherein an increase in the level of expression of said nucleic acid molecule relative to the normal level of expression of said nucleic acid molecule in an individual is indicative of the onset or predisposition to the onset of a neoplasm.

2. A method for determining the onset or a predisposition to the onset of a neoplasm in an individual, said method comprising measuring the level of expression of one or more:

- (i) nucleic acid molecules comprising a nucleotide sequence substantially as set forth in any one of SEQ ID NOs: 73-219 or a functional derivative, variant or homologue of said nucleic acid molecule; or
- (ii) nucleic acid molecules comprising a nucleotide sequence capable of hybridising any one or more of the sequences of (i) under low stringency

- 131 -

conditions at 42°C or a functional derivative, variant or homologue of said nucleic acid molecule

in a biological sample from said individual wherein an increase in the level of expression of said nucleic acid molecule relative to the normal level of expression of said nucleic acid molecule in an individual is indicative of the onset or predisposition to the onset of a neoplasm.

3. A method for determining the onset or a predisposition to the onset of a neoplasm in an individual, said method comprising measuring the level of expression of one or more:

- (i) nucleic acid molecules comprising a nucleotide sequence substantially as set forth in any one of SEQ ID NOs: 220-336 or a functional derivative, variant or homologue of said nucleic acid molecule; or
- (ii) nucleic acid molecules comprising a nucleotide sequence capable of hybridising any one or more of the sequences of (i) under low stringency conditions at 42°C or a functional derivative, variant or homologue of said nucleic acid molecule

in a biological sample from said individual wherein an increase in the level of expression of said nucleic acid molecule relative to the normal level of expression of said nucleic acid molecule in an individual is indicative of the onset or predisposition to the onset of a neoplasm.

4. The method according to claim 1 wherein said nucleotide sequence is SEQ ID NO: 2 or SEQ ID NO: 30 and said level of upregulation is more than 100 fold the normal level.

5. The method according to claim 1 wherein said nucleotide sequence is SEQ ID NO: 7, SEQ ID NO: 14, SEQ ID NOs: 20-21, SEQ ID NOs: 27-29, and said level of upregulation is 10-100 fold the normal level.

- 132 -

6. The method according to claim 1 wherein said nucleotide sequence is SEQ ID NO: 38, SEQ ID NO: 43, SEQ ID NO: 49, SEQ ID NOs: 60-62 or SEQ ID NO: 66 and said level of upregulation is 4.5-10.5 fold the normal level.

7. The method according to claim 1 wherein said nucleotide sequence is SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 17, SEQ ID NO: 32, SEQ ID NO: 38, SEQ ID NO: 53, SEQ ID NO: 36, SEQ ID NO: 64 or SEQ ID NO: 68 and said level of upregulation is 1.5-4 fold the normal level.

8. The method according to claim 1 wherein said nucleotide sequence is SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NOs: 18-19, SEQ ID NO: 31, SEQ ID NOs: 35-36, SEQ ID NOs: 40-41, SEQ ID NOs: 45-46, SEQ ID NOs: 51-52, SEQ ID NOs: 54-55, SEQ ID NO: 59, SEQ ID NO: 65, SEQ ID NO: 72 or SEQ ID NOs: 337-338.

9. The method according to claim 1 wherein said nucleotide sequence is SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 14, SEQ ID NOs: 20-21, SEQ ID NOs: 27-29, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 38, SEQ ID NO: 43, SEQ ID NO: 49, SEQ ID NO: 53, SEQ ID NO: 56, SEQ ID NO: 60, SEQ ID NO: 62 or SEQ ID NO: 66.

10. The method according to claim 1 wherein said nucleotide sequence is SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 14, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NOs: 27-29, SEQ ID NO: 38, SEQ ID NO: 43, SEQ ID NO: 49, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66 or SEQ ID NO: 68.

11. The method according to claim 1 wherein said nucleotide sequence is SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 14, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NOs: 27-29, SEQ ID NO: 38, SEQ ID NO: 43, SEQ ID NO: 49, SEQ ID NO: 53, SEQ ID NO: 56, SEQ ID NO: 60, SEQ ID NO: 62 or SEQ ID NO: 66.

- 133 -

12. The method according to claim 11 wherein said nucleotide sequence is SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 14, SEQ ID NO: 43 or SEQ ID NO: 62.

13. The method according to any one of claims 1, 2 or 3 wherein the subject of detection is the expression product of said nucleic acid sequence.

14. The method according to any one of claims 1, 2, 3 or 13 wherein said neoplasm is an adenoma.

15. The method according to claim 14 wherein said adenoma is a colorectal adenoma.

16. A method for determining the onset or predisposition to the onset of a neoplasm in an individual, said method comprising detecting the co-expression of any two or more:

- (i) nucleic acid molecules comprising a nucleotide sequence substantially as set forth in any one of SEQ ID NOs: 1-2, SEQ ID NOs: 4-6, SEQ ID NOs: 8-32, SEQ ID NOs: 35-37, SEQ ID NO: 38, SEQ ID NOs: 40-43, SEQ ID NOs: 45-49, SEQ ID NOs: 51-56, SEQ ID NOs: 58-60, SEQ ID NO: 62, SEQ ID NOs: 64-66, SEQ ID NOs: 68-72 or SEQ ID NOs: 337-338 or a functional derivative, variant or homologue of said nucleic acid molecule; or
- (ii) nucleic acid molecules comprising a nucleotide sequence capable of hybridising any two or more of the sequences of (i) under low stringency conditions at 42°C or a functional derivative, variant or homologue of said nucleic acid molecule

in one or more biological samples from said individual wherein the co-expression of said nucleic acid molecules is indicative of the onset or predisposition to the onset of a neoplasm.

17. A method for determining the onset or predisposition to the onset of a neoplasm in an individual, said method comprising detecting the co-expression of any two or more:

- 134 -

- (i) nucleic acid molecules comprising a nucleotide sequence substantially as set forth in any one of SEQ ID NOs: 73-219 or a functional derivative, variant or homologue of said nucleic acid molecule; or
- (ii) nucleic acid molecules comprising a nucleotide sequence capable of hybridising any two or more of the sequences of (i) under low stringency conditions at 42°C or a functional derivative, variant or homologue of said nucleic acid molecule

in one or more biological samples from said individual wherein the co-expression of said nucleic acid molecules is indicative of the onset or predisposition to the onset of a neoplasm.

18. A method for determining the onset or predisposition to the onset of a neoplasm in an individual, said method comprising detecting the co-expression of any two or more:

- (i) nucleic acid molecules comprising a nucleotide sequence substantially as set forth in any one of SEQ ID NOs: 220-336 or a functional derivative, variant or homologue of said nucleic acid molecule; or
- (ii) nucleic acid molecules comprising a nucleotide sequence capable of hybridising any two or more of the sequences of (i) under low stringency conditions at 42°C or a functional derivative, variant or homologue of said nucleic acid molecule

in one or more biological samples from said individual wherein the co-expression of said nucleic acid molecules is indicative of the onset or predisposition to the onset of a neoplasm.

19. The method according to claim 16 wherein said nucleotide sequence co-expression is the co-expression of any three of SEQ ID NO: 7, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 24, SEQ ID NO: 65, SEQ ID NO: 19, SEQ ID NO: 1, SEQ ID NO: 53, SEQ ID

- 135 -

NO: 72, SEQ ID NO: 11 or SEQ ID NO: 26.

20. The method according to claim 19 wherein the subject nucleotide sequences are co-expressed as a profile of three, which profile is selected from the list of:

- (i) SEQ ID NO: 7 and SEQ ID NO: 72 and SEQ ID NO: 11;
- (ii) SEQ ID NO: 7 and SEQ ID NO: 72 and SEQ ID NO: 26;
- (iii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 16;
- (iv) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 1;
- (v) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 24; or
- (vi) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 16.

21. The method according to claim 19 wherein the subject nucleotide sequences are co-expressed as a profile of three, which profile is selected from the list of:

- (i) SEQ ID NO: 7 and SEQ ID NO: 56 and SEQ ID NO: 11;
- (ii) SEQ ID NO: 7 and SEQ ID NO: 64 and SEQ ID NO: 11;
- (iii) SEQ ID NO: 7 and SEQ ID NO: 72 and SEQ ID NO: 11;
- (iv) SEQ ID NO: 7 and SEQ ID NO: 9 and SEQ ID NO: 11; or
- (v) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 11.

22. The method according to claim 15 wherein said nucleotide sequence co-expression is the co-expression of any four of SEQ ID NOs: 4-6, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NOs: 21-22, SEQ ID NOs: 27-29, SEQ ID NOs: 30-31, SEQ ID NO: 36, SEQ ID NOs: 37-38, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NOs: 48-49, SEQ ID NO: 52, SEQ ID NO: 56, SEQ ID NO: 59, SEQ ID NO: 64, SEQ ID NOs: 68-69, SEQ ID NO: 71 or SEQ ID NO: 337.

23. The method according to claim 22 wherein the subject nucleotide sequences are co-expressed as a profile of four, which profile is selected from the list of:

- 136 -

- (i) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 24 and SEQ ID NO: 65;
- (ii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 24 and SEQ ID NO: 19;
- (iii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 53 and SEQ ID NO: 1;
- (iv) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 16 and SEQ ID NO: 19;
- (v) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 16 and SEQ ID NO: 46; or
- (vi) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 65 and SEQ ID NO: 1.

24. The method according to claim 22 wherein the subject nucleotide sequences are co-expressed as a profile of four, which profile is selected from the list of:

- (i) SEQ ID NO: 30 and SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 1;
- (ii) SEQ ID NO: 7 and SEQ ID NO: 43 and SEQ ID NO: 14 and SEQ ID NO: 24;
- (iii) SEQ ID NO: 7 and SEQ ID NO: 43 and SEQ ID NO: 59 and SEQ ID NO: 1;
- (iv) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 49 and SEQ ID NO: 24;
- (v) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 49 and SEQ ID NO: 16;
- (vi) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 49 and SEQ ID NO: 1;
- (vii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 21 and SEQ ID NO: 16;
- (viii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 21 and SEQ ID NO: 1;
- (ix) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NOs: 27-29 and SEQ ID NO: 24;
- (x) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NOs: 27-29 and SEQ ID NO: 16;
- (xi) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NOs: 27-29 and SEQ ID NO: 1;
- (xii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 56 and SEQ ID NO: 1;
- (xiii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 9 and SEQ ID NO: 24;
- (xiv) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 9 and SEQ ID NO: 37;
- (xv) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 9 and SEQ ID NO: 16;
- (xvi) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 9 and SEQ ID NO: 1;
- (xvii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 24 and SEQ ID NO: 16;
- (xviii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 24 and SEQ ID NO: 46;
- (xix) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 24 and SEQ ID NO: 1; or
- (xx) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 24 and SEQ ID NO: 337.

- 137 -

25. The method according to claim 22 wherein the subject nucleotide sequences are co-expressed as a profile of four, which profile is selected from the list of:

- (i) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 5 and SEQ ID NO: 1;
 - (ii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 65 and SEQ ID NO: 16;
 - (iii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 65 and SEQ ID NO: 1;
 - (iv) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 53 and SEQ ID NO: 37;
 - (v) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 53 and SEQ ID NO: 48;
 - (vi) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 68 and SEQ ID NO: 1;
 - (vii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 31 and SEQ ID NO: 1;
 - (viii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 69 and SEQ ID NO: 16;
 - (ix) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 69 and SEQ ID NO: 1;
 - (x) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 52 and SEQ ID NO: 1;
 - (xi) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 16 and SEQ ID NO: 337;
 - (xii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 16 and SEQ ID NO: 71;
 - (xiii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 36 and SEQ ID NO: 1;
 - (xiv) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 19 and SEQ ID NO: 1;
 - (xv) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 40 and SEQ ID NO: 1;
 - (xvi) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 22 and SEQ ID NO: 1;
 - (xvii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 46 and SEQ ID NO: 1;
 - (xviii) SEQ ID NO: 7 and SEQ ID NOs: 27-29 and SEQ ID NO: 24 and SEQ ID NO: 4;
 - (xix) SEQ ID NO: 7 and SEQ ID NOs: 27-29 and SEQ ID NO: 65 and SEQ ID NO: 11;
- or
- (xx) SEQ ID NO: 7 and SEQ ID NO: 38 and SEQ ID NO: 64 and SEQ ID NO: 13.

26. The method according to claim 22 wherein the subject nucleotide sequences are co-expressed as a profile of four, which profile is selected from the list of:

- (i) SEQ ID NO: 7 and SEQ ID NO: 9 and SEQ ID NO: 68 and SEQ ID NO: 11;
- (ii) SEQ ID NO: 7 and SEQ ID NO: 24 and SEQ ID NO: 69 and SEQ ID NO: 11;
- (iii) SEQ ID NO: 7 and SEQ ID NO: 64 and SEQ ID NO: 53 and SEQ ID NO: 11;

- 138 -

- (iv) SEQ ID NO: 7 and SEQ ID NO: 64 and SEQ ID NO: 68 and SEQ ID NO: 11;
- (v) SEQ ID NO: 7 and SEQ ID NO: 64 and SEQ ID NO: 69 and SEQ ID NO: 13;
- (vi) SEQ ID NO: 7 and SEQ ID NO: 64 and SEQ ID NO: 36 and SEQ ID NO: 13;
- (vii) SEQ ID NO: 7 and SEQ ID NO: 64 and SEQ ID NO: 11 and SEQ ID NO: 337;
- (viii) SEQ ID NO: 7 and SEQ ID NO: 53 and SEQ ID NO: 72 and SEQ ID NO: 11;
- (ix) SEQ ID NO: 7 and SEQ ID NO: 72 and SEQ ID NO: 26 and SEQ ID NO: 46;
- (x) SEQ ID NO: 7 and SEQ ID NO: 72 and SEQ ID NO: 36 and SEQ ID NO: 11;
- (xi) SEQ ID NO: 7 and SEQ ID NO: 72 and SEQ ID NO: 46 and SEQ ID NO: 11;
- (xii) SEQ ID NO: 7 and SEQ ID NO: 69 and SEQ ID NO: 46 and SEQ ID NO: 11;
- (xiii) SEQ ID NO: 43 and SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 24;
- (xiv) SEQ ID NO: 43 and SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 16;
- (xv) SEQ ID NO: 43 and SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 1;
- (xvi) SEQ ID NO: 43 and SEQ ID NO: 7 and SEQ ID NOS: 27-29 and SEQ ID NO: 24;
- (xvii) SEQ ID NO: 43 and SEQ ID NO: 7 and SEQ ID NO: 36 and SEQ ID NO: 11;
- (xviii) SEQ ID NO: 43 and SEQ ID NO: 7 and SEQ ID NO: 59 and SEQ ID NO: 1;
- (xix) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 49 and SEQ ID NO: 24; or
- (xx) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 49 and SEQ ID NO: 22.

27. The method according to claim 22 wherein the subject nucleotide sequences are co-expressed as a profile of four, which profile is selected from the list of:

- (i) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 49 and SEQ ID NO: 1;
- (ii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 56 and SEQ ID NO: 1;
- (iii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 56 and SEQ ID NO: 1;
- (iv) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 9 and SEQ ID NO: 1;
- (v) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 24 and SEQ ID NO: 19;
- (vi) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 65 and SEQ ID NO: 37;
- (vii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 53 and SEQ ID NO: 48;
- (viii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 53 and SEQ ID NO: 1;
- (ix) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 72 and SEQ ID NO: 1;
- (x) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 69 and SEQ ID NO: 16;

- 139 -

- (xi) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 16 and SEQ ID NO: 19;
- (xii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 19 and SEQ ID NO: 1;
- (xiii) SEQ ID NO: 7 and SEQ ID NO: 14 and SEQ ID NO: 1 and SEQ ID NO: 71;
- (xiv) SEQ ID NO: 7 and SEQ ID NO: 49 and SEQ ID NO: 64 and SEQ ID NO: 11;
- (xv) SEQ ID NO: 7 and SEQ ID NO: 38 and SEQ ID NO: 56 and SEQ ID NO: 13;
- (xvi) SEQ ID NO: 7 and SEQ ID NO: 38 and SEQ ID NO: 56 and SEQ ID NO: 13;
- (xvii) SEQ ID NO: 7 and SEQ ID NO: 56 and SEQ ID NO: 64 and SEQ ID NO: 11;
- (xviii) SEQ ID NO: 7 and SEQ ID NO: 56 and SEQ ID NO: 53 and SEQ ID NO: 6;
- (xix) SEQ ID NO: 7 and SEQ ID NO: 9 and SEQ ID NO: 64 and SEQ ID NO: 16; or
- (xx) SEQ ID NO: 7 and SEQ ID NO: 9 and SEQ ID NO: 64 and SEQ ID NO: 13.

28. The method according to claim 22 wherein the subject nucleotide sequences are co-expressed as a profile of four, which profile is selected from the list of:

- (i) SEQ ID NO: 7 and SEQ ID NO: 9 and SEQ ID NO: 68 and SEQ ID NO: 11;
- (ii) SEQ ID NO: 7 and SEQ ID NO: 24 and SEQ ID NO: 72 and SEQ ID NO: 13;
- (iii) SEQ ID NO: 7 and SEQ ID NO: 24 and SEQ ID NO: 72 and SEQ ID NO: 46;
- (iv) SEQ ID NO: 7 and SEQ ID NO: 24 and SEQ ID NO: 72 and SEQ ID NO: 71;
- (v) SEQ ID NO: 7 and SEQ ID NO: 64 and SEQ ID NO: 72 and SEQ ID NO: 16;
- (vi) SEQ ID NO: 7 and SEQ ID NO: 64 and SEQ ID NO: 68 and SEQ ID NO: 11;
- (vii) SEQ ID NO: 7 and SEQ ID NO: 64 and SEQ ID NO: 69 and SEQ ID NO: 11;
- (viii) SEQ ID NO: 7 and SEQ ID NO: 64 and SEQ ID NO: 19 and SEQ ID NO: 11;
- (ix) SEQ ID NO: 7 and SEQ ID NO: 64 and SEQ ID NO: 13 SEQ ID NO: 11;
- (x) SEQ ID NO: 7 and SEQ ID NO: 53 and SEQ ID NO: 72 and SEQ ID NO: 11;
- (xi) SEQ ID NO: 7 and SEQ ID NO: 53 and SEQ ID NO: 15 and SEQ ID NO: 11;
- (xii) SEQ ID NO: 7 and SEQ ID NO: 72 and SEQ ID NO: 68 and SEQ ID NO: 11;
- (xiii) SEQ ID NO: 7 and SEQ ID NO: 72 and SEQ ID NO: 69 and SEQ ID NO: 11;
- (xiv) SEQ ID NO: 7 and SEQ ID NO: 72 and SEQ ID NO: 36 and SEQ ID NO: 11;
- (xv) SEQ ID NO: 7 and SEQ ID NO: 72 and SEQ ID NO: 19 and SEQ ID NO: 11;
- (xvi) SEQ ID NO: 7 and SEQ ID NO: 72 and SEQ ID NO: 46 and SEQ ID NO: 11;
- (xvii) SEQ ID NO: 7 and SEQ ID NO: 72 and SEQ ID NO: 46 and SEQ ID NO: 1;

- 140 -

- (xviii) SEQ ID NO: 7 and SEQ ID NO: 68 and SEQ ID NO: 16 and SEQ ID NO: 36; or
- (xix) SEQ ID NO: 7 and SEQ ID NO: 68 and SEQ ID NO: 36 and SEQ ID NO: 11.

29. The method according to any one of claims 16, 17 or 18 wherein the subject detection is directed to the expression product of said nucleic acid sequences.

30. The method according to any one of claims 16, 17, 18 or 29 wherein said neoplasm is an adenoma.

31. The method according to claim 30 wherein said adenoma is a colorectal adenoma.

32. The method according to any one of claims 1, 2, 3, 16, 17 or 18 wherein said method is directed to monitoring for the onset or progression of said neoplasm in an individual.

33. The method according to any one of claims 14, 15, 30 or 31 wherein said biological sample is a stool sample, any other biological sample of gastrointestinal origin or a biopsy sample.

34. An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NO: 1 or SEQ ID NO: 6 or SEQ ID NOs: 8-10 or derivative or homologue thereof, or capable of hybridising to any one or more of SEQ ID NO: 1 or SEQ ID NO: 6 or SEQ ID NOs: 8-10 under low stringency conditions at 42°C.

35. An isolated nucleic acid molecule according to claim 34 substantially as set forth in any one or more of SEQ ID NO: 1, SEQ ID NO: 6 or SEQ ID NOs: 8-10.

36. An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NO: 4 or SEQ ID NO: 5 or derivative or homologue thereof, or capable of hybridising to

- 141 -

any one or more of SEQ ID NO: 4 or SEQ ID NO: 5 under low stringency conditions at 42°C.

37. An isolated nucleic acid molecule according to claim 36 substantially as set forth in any one or more of SEQ ID NO: 4 or SEQ ID NO: 5.

38. An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NO: 7 or derivative or homologue thereof, or capable of hybridising to any one or more of SEQ ID NO: 7 under low stringency conditions at 42°C.

39. An isolated nucleic acid molecule according to claim 38 substantially as set forth in SEQ ID NO: 7.

40. An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NOs: 11-13 or SEQ ID NOs: 15-16 or derivative or homologue thereof, or capable of hybridising to any one or more of SEQ ID NOs: 11-13 or SEQ ID NOs: 15-16 under low stringency conditions at 42°C.

41. An isolated nucleic acid molecule according to claim 40 substantially as set forth in any one or more of SEQ ID NOs: 11-13 or SEQ ID NOs: 15-16.

42. An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NO: 14 or derivative or homologue thereof, or capable of hybridising to any one or more of SEQ ID NO: 14 under low stringency conditions at 42°C.

43. An isolated nucleic acid molecule according to claim 42 substantially as set forth in SEQ ID NO: 14.

- 142 -

44. An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NOs: 17-19 or SEQ ID NOs: 22-23 or derivative or homologue thereof, or capable of hybridising to any one or more of SEQ ID NOs: 17-19 or SEQ ID NOs: 22-23 under low stringency conditions at 42°C.

45. An isolated nucleic acid molecule according to claim 44 substantially as set forth in any one or more of SEQ ID NOs: 17-19 or SEQ ID NOs: 22-23.

46. An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NO: 20 or derivative or homologue thereof, or capable of hybridising to any one or more of SEQ ID NO: 20 under low stringency conditions at 42°C.

47. An isolated nucleic acid molecule according to claim 46 substantially as set forth in SEQ ID NO: 20.

48. An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NO: 21 or derivative or homologue thereof, or capable of hybridising to any one or more of SEQ ID NO: 21 under low stringency conditions at 42°C.

49. An isolated nucleic acid molecule according to claim 48 substantially as set forth in SEQ ID NO: 21.

50. An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NOs: 24-26, SEQ ID NO: 31 or SEQ ID NOs: 35-37 or derivative or homologue thereof, or capable of hybridising to any one or more of SEQ ID NOs: 24-26, SEQ ID NO: 31 or SEQ ID NOs: 35-37 under low stringency conditions at 42°C.

- 143 -

51. An isolated nucleic acid molecule according to claim 50 substantially as set forth in any one or more of SEQ ID NOs: 24-26, SEQ ID NO: 31 or SEQ ID NOs: 35-37.

52. An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NO: 27, SEQ ID NO: 28 or SEQ ID NO: 29 or derivative or homologue thereof, or capable of hybridising to any one or more of SEQ ID NO: 27, SEQ ID NO: 28 or SEQ ID NO: 29 under low stringency conditions at 42°C.

53. An isolated nucleic acid molecule according to claim 53 substantially as set forth in any one or more of SEQ ID NO: 27, SEQ ID NO: 28 or SEQ ID NO: 29.

54. An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NO: 30 or derivative or homologue thereof, or capable of hybridising to any one or more of SEQ ID NO: 30 under low stringency conditions at 42°C.

55. An isolated nucleic acid molecule according to claim 54 substantially as set forth in SEQ ID NO: 30.

56. An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NO: 59 or derivative or homologue thereof, or capable of hybridising to any one or more of SEQ ID NO: 59 under low stringency conditions at 42°C.

57. An isolated nucleic acid molecule according to claim 34 substantially as set forth in SEQ ID NO: 59.

58. An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID

- 144 -

NOs: 73-147 or derivative or homologue thereof, or capable of hybridising to any one or more of SEQ ID NOs: 73-147 under low stringency conditions at 42°C.

59. An isolated nucleic acid molecule according to claim 58 substantially as set forth in any one or more of SEQ ID NOs: 73-147.

60. An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NOs: 145-219 or SEQ ID NO: 336 or derivative or homologue thereof, or capable of hybridising to any one or more of SEQ ID NOs: 145-219 or SEQ ID NO: 336 under low stringency conditions at 42°C.

61. An isolated nucleic acid molecule according to claim 60 substantially as set forth in any one or more of SEQ ID NOs: 146-219 or SEQ ID NO: 336.

62. An isolated nucleic acid molecule according to any one of claims 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58 or 60 wherein said molecule is genomic DNA.

63. An isolated nucleic acid molecule according to any one of claims 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58 or 60 wherein said molecule is cDNA.

64. A protein encoded by a nucleotide sequence or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NO: 1, SEQ ID NO: 6 or SEQ ID NOs: 8-10 or a derivative, homologue, analogue, chemical equivalent or mimetic or said protein.

65. A protein encoded by a nucleotide sequence or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NO: 4 or SEQ ID NO: 5 or a derivative, homologue, analogue, chemical equivalent or mimetic or said protein.

- 145 -

66. A protein encoded by a nucleotide sequence or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in SEQ ID NO: 7 or a derivative, homologue, analogue, chemical equivalent or mimetic or said protein.

67. A protein encoded by a nucleotide sequence or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NOs: 11-13 or SEQ ID NOs: 15-16 or a derivative, homologue, analogue, chemical equivalent or mimetic or said protein.

68. A protein encoded by a nucleotide sequence or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in SEQ ID NO: 14 or a derivative, homologue, analogue, chemical equivalent or mimetic or said protein.

69. A protein encoded by a nucleotide sequence or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NOs: 17-19 or SEQ ID NOs: 22-23 or a derivative, homologue, analogue, chemical equivalent or mimetic or said protein.

70. A protein encoded by a nucleotide sequence or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in SEQ ID NO: 20 or a derivative, homologue, analogue, chemical equivalent or mimetic or said protein.

71. A protein encoded by a nucleotide sequence or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in SEQ ID NO: 21 or a derivative, homologue, analogue, chemical equivalent or mimetic or said protein.

72. A protein encoded by a nucleotide sequence or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NOs: 24-26, SEQ ID NO: 31 or SEQ ID NOs: 35-37 or a derivative, homologue, analogue, chemical equivalent or mimetic or said protein.

- 146 -

73. A protein encoded by a nucleotide sequence or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in any one or more of SEQ ID NO: 27 or SEQ ID NO: 28 or SEQ ID NO: 29 or a derivative, homologue, analogue, chemical equivalent or mimetic or said protein.

74. A protein encoded by a nucleotide sequence or derivative, homologue or analogue thereof comprising a nucleotide sequence capable of hybridising to the nucleotide sequences as set forth in SEQ ID NO: 30 or a derivative, homologue or analogue thereof under low stringency conditions or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.

75. A protein encoded by a nucleotide sequence or derivative, homologue or analogue thereof comprising a nucleotide sequence capable of hybridising to the nucleotide sequences as set forth in SEQ ID NO: 59 or a derivative, homologue or analogue thereof under low stringency conditions or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.

76. A protein encoded by a nucleotide sequence or derivative, homologue or analogue thereof comprising a nucleotide sequence capable of hybridising to any one or more of the nucleotide sequences as set forth in any one or more of SEQ ID NOs: 73-145 or a derivative, homologue or analogue thereof under low stringency conditions or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.

77. A protein encoded by a nucleotide sequence or derivative, homologue or analogue thereof comprising a nucleotide sequence capable of hybridising to any one or more of the nucleotide sequences as set forth in any one or more of SEQ ID NOs: 146-219 or SEQ ID NO: 336 or a derivative, homologue or analogue thereof under low stringency conditions or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.

78. A method for the treatment and/or prophylaxis of a condition characterised by aberrant, unwanted or otherwise inappropriate cell growth in a subject, said method

- 147 -

comprising administering to said subject an effective amount of an agent for a time and under conditions sufficient to modulate expression of the nucleic acid molecules of any one of claims 34-63 and/or the functional activity of the protein molecules of any one of claims 64-77.

79. The method according to claim 78 wherein said condition is a neoplastic condition.

80. The method according to claim 79 wherein said neoplastic condition is an adenoma.

81. The method according to claim 80 wherein said adenoma is a colorectal adenoma.

82. A diagnostic kit for assaying biological samples comprising an agent for detecting the nucleic acid molecule of any one or more *of claims 34-63* and/or the protein molecules of any one of claims 64-77 and reagents useful for facilitating the detection by the agent in the first compartment.